Novartis a anunțat astăzi vestea dificilă că oprește studiul VIBRANT-HD cu Branaplam, după ce unii participanți au prezentat efecte secundare.
Chiar dacă aceste vești pot fi dezamăgitoare, comunitatea HD va rămâne pozitivă și speră ca testele și analizele rămase să aducă vești bune.
SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating a unique profile with robust improvements of chorea in Huntington’s Disease Patients and a safe profile with no somnolence, no akathisia and no impact Citește mai mult...
The International Huntington Association, in collaboration with the European Huntington Association, is organizing a campaign for Rare Disease Day 2025, on the 28th February. The slogan for this year’s RDD is “More than you can Citește mai mult...
Rare Diseases International (RDI), announced the launch of the RDI Youth Leadership Programme, an initiative designed to engage and empower young people within the rare disease community. This programme aims to ensure that the perspectives Citește mai mult...
Romanian 
English 
Arabic 
Bulgarian 
Chinese 
Czech 
Danish 
Dutch 
Estonian 
Finnish 
French 
German 
Greek 
Hungarian 
Indonesian 
Italian 
Japanese 
Latvian 
Lithuanian 
Polish 
Portuguese 
Russian 
Slovak 
Slovenian 
Spanish 
Swedish 
Turkish 
Ukrainian
0 de comentarii